H. Deng

ORCID: 0000-0002-5499-8991
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chromatin Remodeling and Cancer
  • Sarcoma Diagnosis and Treatment
  • Circadian rhythm and melatonin
  • Dietary Effects on Health
  • Hydrogen Storage and Materials
  • Lung Cancer Diagnosis and Treatment
  • Diabetes Treatment and Management
  • Lung Cancer Treatments and Mutations
  • Metabolism, Diabetes, and Cancer
  • Ammonia Synthesis and Nitrogen Reduction
  • Carbon dioxide utilization in catalysis
  • Mechanisms of cancer metastasis
  • Pharmacology and Obesity Treatment
  • Regulation of Appetite and Obesity
  • Cancer Immunotherapy and Biomarkers

Fourth Hospital of Hebei Medical University
2025

Hebei Medical University
2025

South China University of Technology
2024

Guangzhou Medical University
2024

Guangzhou First People's Hospital
2024

Sichuan University
2022

West China Hospital of Sichuan University
2022

Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing soft tissue sarcoma of the skin, representing less than 1% all sarcomas. Clinically, it characterized by its indolent nature, localized growth, and low-grade malignant fibrosarcoma features. Here, we present case 40-year-old woman diagnosed with DFSP carrying deletion in SMARCA4 gene. Following complete tumour resection, no recurrence or new malignancies were observed during 1-year follow-up period. To our knowledge, cases gene...

10.1177/30502098251318875 article EN 2025-01-01

The benefit of neoadjuvant immunotherapy and chemotherapy in resectable NSCLC indicated that this combination therapy may provide more surgical opportunities survival benefits to potentially locally advanced NSCLC. Herein, we initiated a phase II study evaluate the feasibility plus stage IIIA/IIIB We planned recruit 33 patients (pts) with EGFR/ALK/ROS wild-type Eligible pts received 2 cycles chemoimmunotherapy (PD-1 inhibitor TIS, nab-paclitaxel, cisplatin/carboplatin) were reassessed for...

10.1016/j.iotech.2022.100186 article EN cc-by-nc-nd Immuno-Oncology Technology 2022-12-01
Coming Soon ...